[{"id":"c5069877-91bb-4251-94b9-54a5d23f9ae6","acronym":"LuMIERE","url":"https://clinicaltrials.gov/study/NCT04939610","created_at":"2023-10-21T07:12:22.742Z","updated_at":"2025-02-25T14:40:52.491Z","phase":"Phase 1/2","brief_title":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","source_id_and_acronym":"NCT04939610 - LuMIERE","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lutetium Lu 177 rofapitide tetraxetan (AAA614)"],"overall_status":"Recruiting","enrollment":" Enrollment 222","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2025-02-14"},{"id":"98c1a72a-f82b-4bd2-a82b-8f84a4d24528","acronym":"","url":"https://clinicaltrials.gov/study/NCT04171219","created_at":"2021-01-18T20:20:56.539Z","updated_at":"2025-02-25T15:11:22.085Z","phase":"Phase 2","brief_title":"Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers","source_id_and_acronym":"NCT04171219","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • talabostat (BXCL701)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 03/19/2020","start_date":" 03/19/2020","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2025-02-13"},{"id":"5d9e3655-cb50-477b-86ac-5e2e42b0f19d","acronym":"BP42675","url":"https://clinicaltrials.gov/study/NCT04826003","created_at":"2021-04-01T16:52:30.647Z","updated_at":"2024-07-02T16:34:37.780Z","phase":"Phase 1/2","brief_title":"Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment","source_id_and_acronym":"NCT04826003 - BP42675","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CEACAM5","pipe":" | ","alterations":" CEACAM5 expression • CEACAM5 overexpression","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CEACAM5 expression • CEACAM5 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • RG7827 • cibisatamab (RG7802)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 07/14/2021","start_date":" 07/14/2021","primary_txt":" Primary completion: 12/27/2024","primary_completion_date":" 12/27/2024","study_txt":" Completion: 12/27/2024","study_completion_date":" 12/27/2024","last_update_posted":"2024-06-06"},{"id":"23956507-6f6e-456a-86d1-530788914d8c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05410743","created_at":"2022-06-08T11:58:16.092Z","updated_at":"2024-07-02T16:35:09.466Z","phase":"Phase 1","brief_title":"Evaluatioon of 177Lu-TATE-EB-01（LNC1010）in SSTR2-positive Tumors","source_id_and_acronym":"NCT05410743","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" SSTR • FAP","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR • FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 177Lu-LNC1010"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-16"},{"id":"40f68034-9538-482f-b97c-8b7b4156cc53","acronym":"","url":"https://clinicaltrials.gov/study/NCT05518903","created_at":"2022-08-29T13:03:00.779Z","updated_at":"2024-07-02T16:35:28.498Z","phase":"Phase 2","brief_title":"An Investigational Scan (68Ga-FAPI-46 PET/CT) for the Imaging of Cancer-Associated Fibroblasts in Patients With Localized Pancreatic Ductal Adenocarcinoma","source_id_and_acronym":"NCT05518903","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • CA 19-9","pipe":"","alterations":" ","tags":["KRAS • CA 19-9"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 11/15/2022","start_date":" 11/15/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2023-11-21"},{"id":"6b3ea990-8167-4dc6-ab05-279352bba7ae","acronym":"","url":"https://clinicaltrials.gov/study/NCT03875079","created_at":"2021-01-18T19:06:21.197Z","updated_at":"2024-07-02T16:35:52.073Z","phase":"Phase 1","brief_title":"A Study To Evaluate Safety And Therapeutic Activity Of RO6874281 In Combination With Pembrolizumab, In Participants With Advanced Or Metastatic Melanoma","source_id_and_acronym":"NCT03875079","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • BRAF • CD8 • FOXP3","pipe":" | ","alterations":" BRAF mutation","tags":["PD-L1 • BRAF • CD8 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • simlukafusp alfa (RG7461)"],"overall_status":"Completed","enrollment":" Enrollment 83","initiation":"Initiation: 06/24/2019","start_date":" 06/24/2019","primary_txt":" Primary completion: 07/14/2022","primary_completion_date":" 07/14/2022","study_txt":" Completion: 07/14/2022","study_completion_date":" 07/14/2022","last_update_posted":"2023-03-29"},{"id":"37a4bacd-4a1a-4ca6-b11b-c51612a5ace1","acronym":"","url":"https://clinicaltrials.gov/study/NCT03063762","created_at":"2021-01-18T15:05:33.057Z","updated_at":"2024-07-02T16:35:55.224Z","phase":"Phase 1b","brief_title":"Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)","source_id_and_acronym":"NCT03063762","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • simlukafusp alfa (RG7461)"],"overall_status":"Completed","enrollment":" Enrollment 69","initiation":"Initiation: 03/20/2017","start_date":" 03/20/2017","primary_txt":" Primary completion: 06/14/2021","primary_completion_date":" 06/14/2021","study_txt":" Completion: 06/14/2021","study_completion_date":" 06/14/2021","last_update_posted":"2023-02-17"},{"id":"88a665b1-a5c9-4bf5-8010-cb1f2a61c47b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04049903","created_at":"2021-01-18T19:51:39.503Z","updated_at":"2024-07-02T16:35:58.685Z","phase":"Phase 1","brief_title":"Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04049903","lead_sponsor":"Molecular Partners AG","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MP0310"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 09/02/2019","start_date":" 09/02/2019","primary_txt":" Primary completion: 06/27/2022","primary_completion_date":" 06/27/2022","study_txt":" Completion: 12/21/2022","study_completion_date":" 12/21/2022","last_update_posted":"2022-12-22"},{"id":"e871cbb4-11ae-42b0-a2ff-04f0f7366402","acronym":"","url":"https://clinicaltrials.gov/study/NCT02627274","created_at":"2021-01-18T12:46:07.584Z","updated_at":"2024-07-02T16:36:00.068Z","phase":"Phase 1a/1b","brief_title":"A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)","source_id_and_acronym":"NCT02627274","lead_sponsor":"Hoffmann-La Roche","biomarkers":" CD20","pipe":" | ","alterations":" EGFR positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Erbitux (cetuximab) • simlukafusp alfa (RG7461)"],"overall_status":"Completed","enrollment":" Enrollment 134","initiation":"Initiation: 12/07/2015","start_date":" 12/07/2015","primary_txt":" Primary completion: 11/10/2022","primary_completion_date":" 11/10/2022","study_txt":" Completion: 11/10/2022","study_completion_date":" 11/10/2022","last_update_posted":"2022-11-22"},{"id":"ff3f2e67-cd18-4c1d-8576-19a17a15974f","acronym":"","url":"https://clinicaltrials.gov/study/NCT02558140","created_at":"2023-10-21T07:12:17.830Z","updated_at":"2024-07-02T16:37:11.848Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of RO6874813 in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02558140","lead_sponsor":"Hoffmann-La Roche","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 10/11/2015","start_date":" 10/11/2015","primary_txt":" Primary completion: 11/06/2017","primary_completion_date":" 11/06/2017","study_txt":" Completion: 11/06/2017","study_completion_date":" 11/06/2017","last_update_posted":"2018-04-04"}]